INSM

Insmed Incorporated

Phase 3 Confirmed

ARIKAYCE

Mycobacterium avium complex (MAC) lung infection

Resolved

106days ago

Phase 3 readout · Mar 23, 2026

What's at stake Phase 3 trial results for ARIKAYCE in Mycobacterium avium complex (MAC) lung infection are due Mar 23, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 16h ago

“Intend to submit data to PDMA to support potential Japanese label expansion in 2H:26”

Add to calendar Post on X Reddit

Provenance